Blog Examines Implications Of Synthetic Artemisinin Production For Global Health

“This week, PATH and our partners celebrated the official launch of the production line for a new synthetic version of artemisinin, the key ingredient for the gold-standard malaria treatment — one that plays a major role in protecting the lives of children and adults worldwide,” PATH President and CEO Steve Davis writes in the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog. “With more than 200 million people sickened and about 650,000 killed by malaria each year, this new source of artemisinin will have a dramatic impact on global efforts to fight malaria and save lives,” he states, adding, “I’m gratified to see the efforts of our strong partnerships come to fruition and to see a growing trend in cross-sector collaboration among our sister organizations in global health” (4/17).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.